Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
CABP1 Antibody, CALBRAIN Antibody, Calcium binding protein 5 Antibody, Calcium-binding protein 1 Antibody, Caldendrin Antibody, CABP Antibody, Calcium binding protein 1 Antibody, HCALB_BR Antibody
Modulates calcium-dependent activity of inositol 1,4,5-triphosphate receptors (ITPRs). Inhibits agonist-induced intracellular calcium signaling. Enhances inactivation and does not support calcium-dependent facilitation of voltage-dependent P/Q-type calcium channels. Causes calcium-dependent facilitation and inhibits inactivation of L-type calcium channels by binding to the same sites as calmodulin in the C-terminal domain of CACNA1C, but resulting in an opposit effects on channel function.
Formalin-fixed and paraffin-embedded human brain tissue reacted with CABP1 antibody , which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
CABP1 Antibody western blot of Jurkat cell line lysates (35 ug/lane). The CABP1 antibody detected the CABP1 protein (arrow).
Western blot of anti-CABP1 Antibody in mouse cerebellum tissue lysates (35 ug/lane). CABP1(arrow) was detected using the purified antibody.
Requested From: United States
Date Requested: 2/21/2017